Immunotherapy in Head and Neck Squamous Cell Carcinoma With PD-L1 Combined Positive Score of Less Than 1

Дата публикации: 17-09-2026 00:00:00

This meta-analysis investigates the association between immune checkpoint inhibitors and improved or reduced survival in patients with head and neck squamous cell carcinoma who have a programmed cell death 1 ligand 1 (PD-L1) combined positive score of less than 1.

Схожие новости

#	Наименование новости	Тональность	Информативность	Дата публикации
1	Is Antigen-Specific Immunotherapy a New Frontier in HPV-Initiated Head and Neck Cancer?	0	10.94	17-09-2026
2	PD-(L)1 Inhibitor Monotherapy vs Chemoimmunotherapy for Advanced NSCLC With High PD-L1 Expression	0	15.58	01-07-2026
3	PDS0101 With Pembrolizumab in HPV16-Positive Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma	0	10.08	17-09-2026
4	Bispecific Antibody Ivonescimab Added to Chemotherapy in EGFR -Variant Non–Small Cell Lung Cancer	0	10	28-07-2026
5	Lipid nanoparticles deliver one-two punch to shrink resistant oral tumors in preclinical models	0	9.5	23-07-2026
6	Ultrasensitive blood test predicts head and neck cancer relapse months earlier	5	7	10-06-2026
7	Rates of Systemic Treatment for Metastatic Non–Small Cell Lung Cancer Among Older Adults	0	5.92	01-07-2026
8	Prostate-Specific Membrane Antigen Imaging and Initial Treatment for Prostate Cancer	0	10.24	01-07-2026
9	Ivonescimab Plus Chemotherapy Improves OS Compared with Tislelizumab Plus Chemotherapy in Previously Untreated Patients with Advanced Squamous NSCLC	0	5	30-06-2026

Классификация: Мнения. Схожих патентов: 0. Схожих новостей: 9. Тональность: 0. Информативность: 12.19. Источник: jamanetwork.com.